Literature DB >> 29274240

Do clinical trials reflect reality? A systematic review of inclusion/exclusion criteria in trials of renal transplant immunosuppression.

Anam A Ayaz-Shah1, Samia Hussain1,2, Simon R Knight1,2.   

Abstract

Renal transplant recipients and donors are becoming increasingly more marginal, with more expanded criteria (ECD) and donation after circulatory death (DCD) donors and older recipients. Despite this, high-risk donors and recipients are often excluded from clinical trials, leading to uncertainty about the generalizability of findings. We extracted data regarding inclusion/exclusion criteria from 174 trials of immunosuppression in renal transplant recipients published over a 5-year period and compared criteria with those specified in published trial registries. Frequently reported donor exclusion criteria were age (16.1%), donor type and cold ischaemic time (22.4%). Common recipient exclusion criteria included upper age limit (38.5%), high panel reactive antibody (PRA) (42.5%) and previous transplantation (39.7%). Inclusion/exclusion criteria recorded in trial registries matched those reported in the manuscript in only 6 (7.8%) trials. Of registered trials, 51 (66.2%) trials included additional criteria in the manuscript, 51 (66.2%) were missing criteria in the manuscript specified in the protocol, and in 19 (24.7%) key criteria changed from the protocol to the manuscript. Our findings suggest many recent immunosuppression trials have restrictive inclusion criteria which may not be reflective of current renal transplant populations. Discrepancies between trial protocols and published reports raise the possibility of selection bias.
© 2017 Steunstichting ESOT.

Entities:  

Keywords:  immunosuppression; kidney transplantation; randomized controlled trials; trial methodology

Mesh:

Year:  2018        PMID: 29274240     DOI: 10.1111/tri.13109

Source DB:  PubMed          Journal:  Transpl Int        ISSN: 0934-0874            Impact factor:   3.782


  2 in total

Review 1.  Overcoming Barriers to Parkinson Disease Trial Participation: Increasing Diversity and Novel Designs for Recruitment and Retention.

Authors:  Pavan A Vaswani; Thomas F Tropea; Nabila Dahodwala
Journal:  Neurotherapeutics       Date:  2020-11-04       Impact factor: 6.088

2.  The IGNITE trial: Participant recruitment lessons prior to SARS-CoV-2.

Authors:  Eric D Vidoni; Amanda Szabo-Reed; Chaeryon Kang; Ashley R Shaw; Jaime Perales-Puchalt; George Grove; Morgan Hamill; Donovan Henry; Jeffrey M Burns; Charles Hillman; Arthur F Kramer; Edward McAuley; Kirk I Erickson
Journal:  Contemp Clin Trials Commun       Date:  2020-10-09
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.